IP Library › Granted Patent US 12,285,428
Granted Patent B2
US 12,285,428 · App. 18/519,782 · Granted Apr 29, 2025

Methods of treating kidney conditions using modified forms of trimetazidine

Inventor: Paul Chamberlin (Brookline, MA)
Assignee: IMBRIA PHARMACEUTICALS, INC.
A61K31/496A61P13/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,428
App. No.
18/519,782
Granted
Apr 29, 2025
Kind
B2
Abstract

The invention provides methods of treating kidney conditions using compositions that contain modified forms of trimetazidine, such as CV-8972. Providing such compositions increases energy production in the kidney. Therefore, methods of the invention are useful for treating a variety of kidney conditions, such as acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.

Claims (22)

1. A method of increasing ATP production in a kidney of a subject, the method comprising providing to a subject having a kidney condition a composition comprising a compound of formula (IX):

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the kidney condition is selected from the group consisting of accumulation of mesangial matrix, acute interstitial nephritis, acute kidney disease, acute tubular necrosis (ATN), Alport syndrome, atherosclerosis, atherosclerotic renal artery stenosis, systemic lupus erythematosus, autosomal dominant polycystic kidney disease (ADPKD), benign prostatic hyperplasia, bladder stones, cancer of the bladder, ureters, or prostate, cell apoptosis, chronic kidney disease, chronic kidney insufficiency, chronic tubulointerstitial nephritis, delayed graft function (DGF) renal, diabetic kidney, diabetic nephropathy, type 1 diabetic nephropathy (TID nephropathy), end-stage renal disease, Focal segmental glomerulosclerosis (FSGS), glomerular basement membrane thickening, glomerular hyperfiltration, glomerular and tubular epithelial hypertrophy, glomerulonephritis, glomerulosclerosis, hemolytic-uremic syndrome, IgA nephropathy (also called Berger's disease), ischemic nephropathy, kidney hypoxia, kidney stones, kidney transplantation, liver cirrhosis, methyl melonic acidosis (MMA), microalbuminuria, obstructed urinary catheter, proteinuria, reduced creatinine clearance, reduced glomerular filtration rate, reflux nephropathy, renal vein thrombosis, and rhabdomyolysis.

3. The method of claim 2 , wherein the kidney condition is acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.

4. The method of claim 1 , wherein the composition is provided orally.

5. The method of claim 1 , wherein the composition is provided is in one dose per day.

6. The method of claim 1 , wherein the composition is provided is in multiple doses per day.

7. The method of claim 1 , wherein the composition is provided in a daily dose comprising from about 25 mg to about 1000 mg of the compound of formula (X).

8. The method of claim 7 , wherein the composition is provided in a daily dose comprising from about 100 mg to about 400 mg of the compound of formula (X).

9. The method of claim 1 , wherein the composition comprises an immediate-release formulation.

10. The method of claim 1 , wherein the composition comprises a modified-release formulation.

11. A method of treating a kidney condition in a subject, the method comprising providing to a subject having a kidney condition a composition comprising a compound of formula (IX):

or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein the kidney condition is selected from the group consisting of accumulation of mesangial matrix, acute interstitial nephritis, acute kidney disease, acute tubular necrosis (ATN), Alport syndrome, atherosclerosis, atherosclerotic renal artery stenosis, systemic lupus erythematosus, autosomal dominant polycystic kidney disease (ADPKD), benign prostatic hyperplasia, bladder stones, cancer of the bladder, ureters, or prostate, cell apoptosis, chronic kidney disease, chronic kidney insufficiency, chronic tubulointerstitial nephritis, delayed graft function (DGF) renal, diabetic kidney, diabetic nephropathy, type 1 diabetic nephropathy (TID nephropathy), end-stage renal disease, Focal segmental glomerulosclerosis (FSGS), glomerular basement membrane thickening, glomerular hyperfiltration, glomerular and tubular epithelial hypertrophy, glomerulonephritis, glomerulosclerosis, hemolytic-uremic syndrome, IgA nephropathy (also called Berger's disease), ischemic nephropathy, kidney hypoxia, kidney stones, kidney transplantation, liver cirrhosis, methyl melonic acidosis (MMA), microalbuminuria, obstructed urinary catheter, proteinuria, reduced creatinine clearance, reduced glomerular filtration rate, reflux nephropathy, renal vein thrombosis, and rhabdomyolysis.

13. The method of claim 12 , wherein the kidney condition is acute kidney disease, chronic kidney disease, chronic kidney insufficiency, diabetic kidney, or diabetic nephropathy.

14. The method of claim 11 , wherein the composition is provided orally.

15. The method of claim 11 , wherein the composition is provided is in one dose per day.

16. The method of claim 11 , wherein the composition is provided is in multiple doses per day.

17. The method of claim 11 , wherein the composition is provided in a daily dose comprising from about 25 mg to about 1000 mg of the compound of formula (X).

18. The method of claim 17 , wherein the composition is provided in a daily dose comprising from about 100 mg to about 400 mg of the compound of formula (X).

19. The method of claim 11 , wherein the composition comprises an immediate-release formulation.

20. The method of claim 11 , wherein the composition comprises a modified-release formulation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2024
From: CHAMBERLIN, PAUL
To: IMBRIA PHARMACEUTICALS, INC.
Reel/Frame 066573/0756 →
Continuity (3)
Continuation 17735594 · May 3, 2022
Provisional Application 63183303 · May 3, 2021
Related Publication 20240091222A1 · Mar 21, 2024
References Cited (180)
US 4100285A · Murai et al. · 1978 [cited by applicant]
US 4166452A · Generales, Jr. · 1979 [cited by applicant]
US 4256108A · Theeuwes · 1981 [cited by applicant]
US 4265874A · Bonsen et al. · 1981 [cited by applicant]
US 4574156A · Morita et al. · 1986 [cited by applicant]
US 4845099A · Ruger et al. · 1989 [cited by applicant]
US 4876257A · Hajos et al. · 1989 [cited by applicant]
US 4885300A · Press et al. · 1989 [cited by applicant]
US 5077288A · Lavielle et al. · 1991 [cited by applicant]
US 5286728A · Ferrini · 1994 [cited by applicant]
US 5340809A · Gaudry et al. · 1994 [cited by applicant]
US 5380726A · Ferrini · 1995 [cited by applicant]
US 5384319A · Ferrini · 1995 [cited by applicant]
US 5397780A · Mizuno et al. · 1995 [cited by applicant]
US 5399557A · Mizuno et al. · 1995 [cited by applicant]
US 5401743A · Rendenbach-Mueller et al. · 1995 [cited by applicant]
US 5428038A · Chatterjee et al. · 1995 [cited by applicant]
US 5527800A · Goto et al. · 1996 [cited by applicant]
US 5591849A · Kato et al. · 1997 [cited by applicant]
US 5641779A · Halazy et al. · 1997 [cited by applicant]
US 5770735A · Emonds-Alt et al. · 1998 [cited by applicant]
US 5776937A · Gante et al. · 1998 [cited by applicant]
US 5849745A · Wierzbicki et al. · 1998 [cited by applicant]
US 5856326A · Anthony et al. · 1999 [cited by applicant]
US 5962448A · Mizuno et al. · 1999 [cited by applicant]
US 5977111A · Mizuno et al. · 1999 [cited by applicant]
US 6087346A · Glennon et al. · 2000 [cited by applicant]
US 6121267A · Glase et al. · 2000 [cited by applicant]
US 6200989B1 · De Cillis et al. · 2001 [cited by applicant]
US 6214841B1 · Jackson et al. · 2001 [cited by applicant]
US 6271223B1 · Mizuno et al. · 2001 [cited by applicant]
US 6331623B1 · Mizuno et al. · 2001 [cited by applicant]
US 6528529B1 · Brann et al. · 2003 [cited by applicant]
US 6562978B1 · Imamura et al. · 2003 [cited by applicant]
US 6693099B2 · Degenhardt et al. · 2004 [cited by applicant]
US 7638531B2 · Mutahi et al. · 2009 [cited by applicant]
US 7666866B2 · Franciskovich et al. · 2010 [cited by applicant]
US 7772251B2 · Sturzebecher et al. · 2010 [cited by applicant]
US 7968538B2 · Becker et al. · 2011 [cited by applicant]
US 8016783B2 · Pastore et al. · 2011 [cited by applicant]
US 8202901B2 · Lopaschuk et al. · 2012 [cited by applicant]
US 8461117B2 · Sufi et al. · 2013 [cited by applicant]
US 8569495B2 · Chassaing et al. · 2013 [cited by applicant]
US 8697661B2 · Kritikou · 2014 [cited by applicant]
US 9096538B2 · Nakamura et al. · 2015 [cited by applicant]
US 9120801B2 · Alisi et al. · 2015 [cited by applicant]
US 10167258B2 · Chuang et al. · 2019 [cited by applicant]
US 10556013B2 · Levin · 2020 [cited by applicant]
US 10918728B2 · Levin · 2021 [cited by applicant]
US 10953102B2 · Levin · 2021 [cited by applicant]
US 11376330B2 · Levin · 2022 [cited by applicant]
US 20030191182A1 · Lopaschuk et al. · 2003 [cited by applicant]
US 20030232877A1 · Sikorski et al. · 2003 [cited by applicant]
US 20040082564A1 · Arrhenius et al. · 2004 [cited by applicant]
US 20050004121A1 · Palani et al. · 2005 [cited by applicant]
US 20070004750A1 · Lorsbach et al. · 2007 [cited by applicant]
US 20080108618A1 · Brann et al. · 2008 [cited by applicant]
US 20080161400A1 · Virsik et al. · 2008 [cited by applicant]
US 20090197891A1 · Lecanu et al. · 2009 [cited by applicant]
US 20090258064A1 · Newell et al. · 2009 [cited by applicant]
US 20100022530A1 · Schiemann et al. · 2010 [cited by applicant]
US 20110046370A1 · Sim et al. · 2011 [cited by applicant]
US 20110137362A1 · Foreman et al. · 2011 [cited by applicant]
US 20110212072A1 · Henkel et al. · 2011 [cited by applicant]
US 20120214818A1 · Dudley · 2012 [cited by applicant]
US 20160060530A1 · Archetti et al. · 2016 [cited by applicant]
US 20160346397A1 · Milne et al. · 2016 [cited by applicant]
US 20170008950A1 · Capon · 2017 [cited by applicant]
US 20170105414A1 · Nakano et al. · 2017 [cited by applicant]
US 20180360975A1 · Levin · 2018 [cited by applicant]
US 20190084917A1 · Savourey et al. · 2019 [cited by applicant]
US 20190216936A1 · Levin · 2019 [cited by applicant]
US 20200138963A1 · Levin · 2020 [cited by applicant]
US 20210353617A1 · Levin · 2021 [cited by examiner]
US 20220168431A1 · Levin · 2022 [cited by examiner]
US 20220249463A1 · Levin et al. · 2022 [cited by applicant]
CA 2170615A1 · 1995 [cited by applicant]
CA 2186010A1 · 1995 [cited by applicant]
CN 101747292B · 2011 [cited by applicant]
DE 2714996A1 · 1977 [cited by applicant]
EP 0144991A2 · 1985 [cited by applicant]
EP 0251141A1 · 1988 [cited by applicant]
EP 615855A1 · 1994 [cited by applicant]
EP 661266A1 · 1995 [cited by applicant]
EP 749967A1 · 1996 [cited by applicant]
EP 1634598A1 · 2006 [cited by applicant]
EP 1886994A1 · 2008 [cited by applicant]
EP 2727916A1 · 2014 [cited by applicant]
JP S57131777 · 1982 [cited by applicant]
JP 2000147773A · 2000 [cited by applicant]
JP 2006113343A · 2006 [cited by applicant]
JP 2015017236A · 2015 [cited by applicant]
RU 2377989C2 · 2010 [cited by applicant]
WO 1995000165A1 · 1995 [cited by applicant]
WO 9626196A2 · 1996 [cited by applicant]
WO 9630054A1 · 1996 [cited by applicant]
WO 9630343A1 · 1996 [cited by applicant]
WO 9728141A1 · 1997 [cited by applicant]
WO 9746549A1 · 1997 [cited by applicant]
WO 9858638A1 · 1998 [cited by applicant]
WO 9950247A1 · 1999 [cited by applicant]
WO 2001005763A2 · 2001 [cited by applicant]
WO 2002058698A2 · 2002 [cited by applicant]
WO 2002064576A1 · 2002 [cited by applicant]
WO 2003006628A2 · 2003 [cited by applicant]
WO 2006027223A1 · 2006 [cited by applicant]
WO 2006117686A2 · 2006 [cited by applicant]
WO 2006133784A1 · 2006 [cited by applicant]
WO 2007075629A2 · 2007 [cited by applicant]
WO 2007096251A1 · 2007 [cited by applicant]
WO 2007116074A1 · 2007 [cited by applicant]
WO 2007116243A2 · 2007 [cited by applicant]
WO 2008109991A1 · 2008 [cited by applicant]
WO 2009015485A1 · 2009 [cited by applicant]
WO 2009058818A2 · 2009 [cited by applicant]
WO 2009066315A2 · 2009 [cited by applicant]
WO 2009156479A1 · 2009 [cited by applicant]
WO 2011032099A1 · 2011 [cited by applicant]
WO 2012049101A1 · 2012 [cited by applicant]
WO 2015018660A1 · 2015 [cited by applicant]
WO 2016005576A1 · 2016 [cited by applicant]
WO 2016107603A1 · 2016 [cited by applicant]
WO 2018236745A1 · 2018 [cited by applicant]
WO 2020081361A1 · 2020 [cited by applicant]
WO 2020243119A1 · 2020 [cited by applicant]
WO 2021225950A1 · 2021 [cited by applicant]
WO 2022150403A1 · 2022 [cited by applicant]
Abrahamsson, 1998, In vitro and in vivo erosion of two different hydrophilic gel matrix tablets, European Journal of Pharmaceuticals and Biopharmaceutics, 46:69-75. [cited by applicant]
Aswathy, 2018, Formulation and Evaluaton of Mucoadhesive Buccal Tablet of Antianginal Drug, IJPPR. Human Journals, 13(1):43-71. [cited by applicant]
Bhosle, 2006, Mutual Prodrug Concept: Fundamentals and Applications, Indian Journal of Pharmaceutical Sciences, May-June, pp. 286-294. [cited by applicant]
Brand, 2013, The role of mitochondrial function and cellular bioenergetics in ageing and disease, British Journal of Dermatology, John Wiley, Hoboken, USA, 169:1-8. [cited by applicant]
Cheng, 2006, Discovery of Potent and Orally Available Malonyl-CoA Decarboxylase Inhibitors as Cardioprotective Agents, J. Med. Chem. 49:4055-4058. [cited by applicant]
Cheng, 2006, Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors, J. Med. Chem. 49:1517-1525. [cited by applicant]
Das, 1995, Essential Fatty Acid Metabolism in Patients with Essential Hypertension, Diabetes Mellitus and Coronary Heart Disease, Prostaglandins Leukotrienes and Essential Fatty Acids, 52, 387-391. [cited by applicant]
Extended European Search Report issued European Application No. 21799968.9, date of mailing: Apr. 4, 2024, 10 pages. [cited by applicant]
Extended European Search Report issued in European Application No. 18821590.9, date of mailing: Oct. 5, 2020, 6 pages. [cited by applicant]
Extended European Search Report issued in European Application No. 19872680.4, date of mailing: Jun. 20, 2022, 7 pages. [cited by applicant]
Extended European Search Report issued in European Application No. 22169109.0, date of mailing: Aug. 30, 2022, 7 pages. [cited by applicant]
Fang, 2011. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle, Journal of Molecular Medicine, 90:31-43. [cited by applicant]
Fillmore, 2014, Malonyl CoA: A Promising Target for the Treatment of Cardiac Disease, Int. Union of Biochem. and Mol. Biol., 66(3):139-146. [cited by applicant]
Fillmore, 2014, Mitochondrial fatty acid oxidation alterations in heart failure, ischemic heart disease and diabetic cardiomyopathy, Brit. J. Pharmacol. 171:2080-2090. [cited by applicant]
Folmes, 2005, Fatty Acid Oxidation Inhibitors in the Management of Chronic Complications of Atherosclerosis, Current Atherosclerosis Reports 2005, 7, 63-70. [cited by applicant]
Gallaher, 1993, Viscosity and Fermentability as Attributes of Dietary Fiber Responsible of the Hypocholesterolemic Effect in Hamsters, J Nutr., 123, pp. 244-252. [cited by applicant]
Gao, 2011, Echocardiography in Mice. Curr Protoc Mouse Biol, 1:71-83. [cited by applicant]
Gibbs, 1995, Cardiac efficiency, Cardiovasc. Res. 30:627-634. [cited by applicant]
Gustafsson, 1999, Characterisation of particle properties and compaction behaviour of hydroxypropyl methylcellulose with different degrees of methoxy/hydroxypropyl substitution, European Journal of Pharmaceutical Scienc… [cited by applicant]
Handbook of Pharmaceutical Excipients, 6th Ed, 2009, pp. 326-329. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/034611, date of mailing: Oct. 14, 2020, 45 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/34608, date of mailing: Oct. 14, 2020, 28 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/34609, date of mailing: Oct. 14, 2020, 22 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2021/039303, date of mailing: Nov. 26, 2021, 19 pages. [cited by applicant]
International Search Report and Written Opinion mailed Nov. 5, 2018, for International Patent Application PCT/US2018/038067 with International filing date Jun. 18, 2018 (11 pages). [cited by applicant]
International Search Report issued in an International Application No. PCT/US2021/030450, date of mailing: Sep. 27, 2021, 9 pages. [cited by applicant]
Kantor, 2000, The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase, Circulation Researc… [cited by applicant]
Kotreka, 2011, Gastroretentive Floating Drug-Delivery Systems: A Critical Review, Critical Reviews in Therapeutic Drug Carrier Systems, 28(1):47-99. [cited by applicant]
Leriche, 2012, Cleavable linkers in chemical biology, Bioorg. Med. Chem. 20:571-582. [cited by applicant]
Levy, 2014, Vasodilators in Acute Heart Failure: Review of the Latest Studies, Curr Emerg Hosp Med Rep, 2 (2): 126-134. [cited by applicant]
Lopaschuk, 2010, Myocardial Fatty Acid Metabolism in Health and Disease, Phys. Rev. 90:207-258. [cited by applicant]
Maskova, 2020, Hypromellose—A traditional pharmaceutical exipient with modern applications in oral and oromucosal drug delivery, Journal of Controlled Release, 324:695-727. [cited by applicant]
Morin, 1998, Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore, Brit. J. Pharmacol. 123:1385-1394. [cited by applicant]
Narokha, 2014, Antioidant effect of nicotinic acid on experimental doxorubicin-induced chronic heart failure, Current Topics in Pharmacology, 18:105-111. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 16/722,691, date of mailing: Aug. 19, 2020, 12 pages. [cited by applicant]
Pubchem, CID 2223657, Jul. 15, 2005, pp. 1-14. [cited by applicant]
Pubchem, CID-57503849, Create Date: Aug. 8, 2012, 16 pages. [cited by applicant]
Reddy, 2006, Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation, Am J Physiol Gastrointest Liver Physiol, 290: G852-G858. [cited by applicant]
Sabbah, 2005, Metabolic Therapy for Heart Disease: Impact of Trimetazidine, Heart Failure Reviews, 10, 281-288. [cited by applicant]
Schipke, 1994, Cardiac efficiency, Basic Res. Cardiol. 89:207-40. [cited by applicant]
Spiekerkoetter, 2010, Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening, J Inherit Metab Dis, 33:527-532. [cited by applicant]
Steggall, 2017, Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure, Diseases, 5(14):1-18. [cited by applicant]
Tang, 2009, The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling, 15 (8):850-856. [cited by applicant]
The Merck Manual List of Diseases https://merckmanuals.com/professional (accessed Jan. 17, 2020), 4 pages. [cited by applicant]
Trammell, 2016, Nicotinamide riboside is uniquely and orally bioavailable in mice and humans, Nat. Commun. 7:12948, 14 pages. [cited by applicant]
Msser, 2008, Measuring cardiac efficiency: is it clinically useful? Heart Metab. 39:3-4. [cited by applicant]
Yong-Hu Fang, 2011, Therapeutic inhibition of fatty acid oxidation in reight ventricular hypertrophy, Journal of Molecular Medicine, Springer, Berlin, DE, 90(1):31-43. [cited by applicant]
Yuasa, 1988, Pharmacological Studies on the Actions of Trimetazidine and Its Derivatives, The Journal of Kansai Medical University, vol. 40, Issue 1, pp. 89-116. [cited by applicant]
Zhou, 2012, Trimetazidine Protects against Smoking-Induced Left Ventricular Remodeling via Attenuating Oxidative Stress, Apoptosis, and Inflammation, PLOS One, 7:1-7. [cited by applicant]
2377989, RU, Tovarystvo Z, Jan. 10, 2010. [cited by applicant]
2020/243119, WO, Imbria Pharmaceuticals, Dec. 3, 2020. [cited by applicant]
2021/225950, WO, Imbria Pharmaceuticals, Nov. 11, 2021. [cited by applicant]
2022/150403, WO, Imbria Pharmaceuticals, Jul. 14, 2022. [cited by applicant]